Please try another search
For the nine months ended 30 September 2019, Innovus Pharmaceuticals Inc revenues decreased 7% to $18M. Net loss decreased 2% to $6M. Revenues reflect Product sales decrease of 6% to $17.4M, Service revenue decrease of 55% to $156K, Cooperative marketing revenue decrease of 37% to $264K. Lower net loss reflects Sales and marketing decrease of 41% to $8.3M (expense), LOSS ON EXTINGUISHMENT OF DEBT decrease of 88% to $125K (expense), Other income (expense).
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 5.75 | 6.85 | 5.36 | 4.75 |
Gross Profit | 3.54 | 4.49 | 3.58 | 4.17 |
Operating Income | -1.7 | -1.31 | -1.5 | -1.66 |
Net Income | -2.24 | -1.76 | -1.99 | -2.16 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 9.51 | 10.84 | 11.37 | 10.13 |
Total Liabilities | 11.51 | 10.79 | 10.31 | 10.02 |
Total Equity | -2 | 0.05 | 1.06 | 0.11 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -1.87 | -1.36 | -0.6 | -6.12 |
Cash From Investing Activities | -0.36 | -0.36 | -0.34 | -0.49 |
Cash From Financing Activities | 1.94 | 2.04 | 1.64 | 6.3 |
Net Change in Cash | -0.29 | 0.33 | 0.7 | -0.32 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review